TROP2 remains hot
Two anti-TROP2 ADCs join cell therapies and Teva’s anti-PD-1 in first-in-human studies.
Lilly takes two shots at the Nectin goal
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
ALX looks to surprise again
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
Can Wee1 be both alive and dead? Schrödinger hopes so
The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.
FDA green and red lights: May 2024
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
Revolution sees a new pan-KRAS challenger
Pfizer moves to take PF-07934040 into its first clinical trial.
BeiGene takes a new approach to a hot target
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Agenus tries again with the FDA
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
Lilly joins the folate receptor arena
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
